Ticker > Company >

Zydus Wellness share price

Zydus Wellness Ltd.

  2.67 L   1.34 K   192 NSE: ZYDUSWELL BSE: 531335 SECTOR: Consumer Food

510.30
+4.85 (0.96%)
NSE: 14 Aug 4:00 PM

Price Summary

Today's High

₹ 513

Today's Low

₹ 504

52 Week High

₹ 611.85

52 Week Low

₹ 367.55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

16235.74 Cr.

Enterprise Value

16407.24 Cr.

No. of Shares

31.82 Cr.

P/E

421.7

P/B

4.02

Face Value

₹ 2

Div. Yield

0.24 %

Book Value (TTM)

₹  126.92

CASH

7.5 Cr.

DEBT

179 Cr.

Promoter Holding

69.64 %

EPS (TTM)

₹  1.21

Sales Growth

64.3%

ROE

0.93 %

ROCE

1.43%

Profit Growth

26.6 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Zydus Wellness Ltd.

Naturell Max Protein Ritebite Complan Glucon-D nycil everyuth Sugar Free Nutralite SugarLite

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year64.3%
3 Year32.33%
5 Year38.6%

Profit Growth

1 Year26.6%
3 Year-17.27%
5 Year17.15%

ROE%

1 Year0.93%
3 Year0.83%
5 Year0.89%

ROCE %

1 Year1.43%
3 Year1.22%
5 Year1.01%

Debt/Equity

0.0444

Price to Cash Flow

461.24

Interest Cover Ratio

5.4364

CFO/PAT (5 Yr. Avg.)

0.675347029428096

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2026 69.64 0.00
Mar 2026 69.63 0.00
Dec 2025 69.63 0.00
Sep 2025 69.63 0.00
Jun 2025 69.63 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 32.3299367182586% for the Past 3 years.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of -5.2767 days.
  • The company has a high promoter holding of 69.64%.

 Limitations

  • The company has shown a poor profit growth of -17.2680510713716% for the Past 3 years.
  • Company has a poor ROE of 0.834533333333333% over the past 3 years.
  • Company has a poor ROCE of 1.22326666666667% over the past 3 years
  • Company has contingent liabilities of 3299.4 Cr.
  • The company is trading at a high PE of 421.7.
  • The company is trading at a high EV/EBITDA of 170.0232.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 140.9 156 152.6 132.6 153
Total Expenditure 125.4 129.1 131.9 112.8 141.2
Operating Profit 15.5 26.9 20.7 19.8 11.8
Other Income 0.7 3.2 4.4 4.8 4.9
Interest 2.3 2.5 3.1 3.1 3
Depreciation 6 6.4 6.3 6.3 6.3
Exceptional Items 0 -9.7 -1.5 0 0
Profit Before Tax 7.9 11.5 14.2 15.2 7.4
Tax 3.3 3.9 2.1 1.9 1.9
Profit After Tax 4.6 7.6 12.1 13.3 5.5
Adjusted EPS (Rs) 0.14 0.24 0.38 0.42 0.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 216.25 251.2 244.8 354.3 582.1
Total Expenditure 221.57 213.2 212 312.8 503.5
Operating Profit -5.32 38 32.8 41.5 78.6
Other Income 15.4 13.8 18.2 13 17.4
Interest 2.02 1.1 2.6 4.5 11
Depreciation 2.84 3.5 3.6 10.2 25
Exceptional Items 0 0 0 0 -11.2
Profit Before Tax 5.22 47.2 44.8 39.8 48.8
Tax -7.48 -19.2 11.1 10.1 11.2
Net Profit 12.7 66.4 33.7 29.7 37.6
Adjusted EPS (Rs.) 0.4 2.09 1.06 0.93 1.18

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 63.63 63.6 63.6 63.6 63.6
Total Reserves 3936.55 3970.7 3972.3 3969.9 3969
Borrowings 0 0 0 44 129
Other N/C liabilities -21.08 -39.3 -28 -15.4 -4.1
Current liabilities 87.43 28.5 75 166 103
Total Liabilities 4066.53 4023.5 4082.9 4228.1 4260.5
Assets
Net Block 45 54.5 54.1 431.9 419.6
Capital WIP 1.77 0.5 4 8 4.9
Intangible WIP 0 0 0 0 0
Investments 3671.25 3671.3 3671.3 3671 3671.2
Loans & Advances 226.73 127.2 221.7 7.6 54
Other N/C Assets 0 0 0 0 0
Current Assets 121.78 170 131.8 109.6 110.8
Total Assets 4066.53 4023.5 4082.9 4228.1 4260.5
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 5.22 47.2 44.8 39.8 48.8
Adjustment -11.25 -8.1 -11.8 3.8 29.9
Changes in Assets & Liabilities -7.51 -2.2 -6.7 -5.6 -41.4
Tax Paid -2.73 -0.2 -0.3 2 -2.1
Operating Cash Flow -16.27 36.7 26 40 35.2
Investing Cash Flow 27.31 0.7 -47.1 -88.4 -32
Financing Cash Flow -37.69 -79.3 15.4 43.4 -0.3
Net Cash Flow -26.65 -41.9 -5.7 -5 2.9

Corporate Actions

Investors Details

PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
promoters 69.63 69.63 69.63 69.63 69.64
late jasodaben babubhai p... - - - - 0.01
zydus family trust(truste... 12.01 12.01 12.01 12.01 12.01
zydus lifesciences limite... 57.59 57.59 57.59 57.59 57.59
jasodaben babubhai patel 0.01 0.01 0.01 0.01 -
PARTICULARS Jun 2025% Sep 2025% Dec 2025% Mar 2026% Jun 2026%
investors 30.37 30.37 30.37 30.37 30.36
investor education and pr... 0.16 0.16 - 0.17 0.17
llp 0.03 0.01 0.01 - 0.02
nippon life india trustee... 6.16 5.74 5.72 5.87 5.91
parag parikh flexi cap fu... 7.27 7.27 7.27 7.33 7.33
quant mutual fund - quant... 4.44 4.43 4.33 4.33 4.23
investor education and pr... - - 0.17 - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CARE RATINGS
Credit CRISIL
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities
Research Edelweiss
Research Edelweiss
Research Edelweiss
Research BOB Capital Market
Research BOB Capital Market
Research Edelweiss
Research Edelweiss
Research Edelweiss
Research Edelweiss
Research Edelweiss
Research ICICI Securities Limited

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY26
Concall Q4FY24
Concall Q3FY24
Concall Q3FY22
Concall Q2FY22
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q3FY26
Presentation Q3FY26
Presentation Q3FY26
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY24
Presentation Q3FY22
Presentation Q1FY25
Presentation Q1FY23
Presentation Q1FY21
Presentation Q1FY20

Company News

Zydus Wellness informs about conference call 10 Aug, 3:54 PM Zydus Wellness - Quaterly Results 5 Aug, 12:00 AM Zydus Wellness informs about newspaper cutting 7 Jul, 4:16 PM Zydus Wellness informs about resignation of SMP 4 Jul, 12:47 PM Zydus Wellness’ arm incorporates wholly owned subsidiary in UAE 25 Jun, 9:42 AM Zydus Wellness’ arm incorporates wholly owned subsidiary in Ireland 24 Jun, 10:57 AM Zydus Wellness informs about investors conference 22 Jun, 10:52 AM Zydus Wellness informs about disclsoure 16 Jun, 11:02 AM Zydus Wellness informs about newspaper publication 28 May, 11:50 AM Zydus Wellness informs about disclosure 26 May, 5:35 PM Zydus Wellness - Quaterly Results 19 May, 12:00 AM Zydus Wellness informs about investor presentation 18 Mar, 10:01 AM Zydus Wellness informs about updates 17 Feb, 5:39 PM Zydus Wellness informs about transcript of conference call 9 Feb, 12:06 PM Zydus Wellness declines on reporting consolidated net loss of Rs 39.90 crore in Q3 4 Feb, 3:10 PM Zydus Wellness reports consolidated net loss of Rs 39.90 crore in Q3 4 Feb, 12:00 PM Zydus Wellness - Quaterly Results 4 Feb, 12:00 AM Zydus Wellness informs about transcript of earnings call 14 Nov, 12:49 PM Zydus Wellness - Quaterly Results 6 Nov, 12:00 AM Zydus Wellness informs about analyst meet 18 Oct, 2:41 PM Zydus Wellness informs about conference call 18 Oct, 2:32 PM Zydus Wellness’ arm acquires UK based Comfort Click 30 Aug, 11:00 AM Zydus Wellness incorporates wholly owned subsidiary in United Kingdom 6 Aug, 9:37 AM Zydus Wellness - Quaterly Results 30 Jul, 1:02 PM Zydus Wellness - Quaterly Results 30 Jul, 1:02 PM Zydus Wellness - Quaterly Results 30 Jul, 1:02 PM Zydus Wellness informs about certificate 10 Jul, 12:04 PM Zydus Wellness informs about update on voluntary liquidation 2 Jul, 10:15 AM Zydus Wellness informs about disclosure 20 Jun, 2:23 PM True North sells entire stake in Zydus Wellness 18 Jun, 12:38 PM Zydus Wellness informs about disclosure 11 Jun, 2:06 PM Zydus Wellness - Quaterly Results 19 May, 12:46 PM Zydus Wellness - Quaterly Results 19 May, 12:46 PM Zydus Wellness - Quaterly Results 19 May, 12:46 PM Zydus Wellness informs about analyst meet 13 May, 5:32 PM Zydus Wellness informs about disclosure 24 Mar, 10:25 AM Zydus Wellness informs about disclosure 13 Mar, 5:02 PM Zydus Wellness gets S&P Global ESG score of 79 for 2024 27 Feb, 11:12 AM Zydus Wellness informs about newspaper cutting 5 Feb, 3:55 PM Zydus Wellness - Quaterly Results 4 Feb, 12:31 PM Zydus Wellness - Quaterly Results 4 Feb, 12:31 PM Zydus Wellness - Quaterly Results 4 Feb, 12:31 PM Zydus Wellness informs about teleconference with investor 27 Jan, 9:59 AM Zydus Wellness informs about receipt of order 24 Jan, 10:04 AM Zydus Wellness informs about board meeting 23 Jan, 12:20 PM Zydus Wellness informs about disclosure 2 Jan, 2:42 PM Zydus Wellness informs about disclosure 28 Dec, 2:59 PM Zydus Wellness acquires remaining equity share capital in Naturell (India) 3 Dec, 10:11 AM Zydus Wellness acquires 98.14% equity share capital in Naturell (India) 30 Nov, 4:37 PM Zydus Wellness informs about updates on acquisition 30 Nov, 10:36 AM

Zydus Wellness Stock Price Analysis and Quick Research Report. Is Zydus Wellness an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Zydus Wellness. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Zydus Wellness has a PE ratio of 421.700685893728 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Zydus Wellness has ROA of 0.8859% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Zydus Wellness has a Current ratio of 1.0757.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Zydus Wellness has a ROE of 0.9323%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Zydus Wellness has a Debt to Equity ratio of 0.0444 which means that the company has low proportion of debt in its capital.

  • Sales growth: Zydus Wellness has reported revenue growth of 64.2958% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Zydus Wellness for the current financial year is 13.5028345645078%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Zydus Wellness is Rs 1.2 and the yield is 0.2352%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Zydus Wellness is Rs 1.2101. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Zydus Wellness in Ticker for free. Also, one can get the intrinsic value of Zydus Wellness by using Valuation Calculators, which are available with a Finology ONE subscription. 

Zydus Wellness FAQs

Q1. What is Zydus Wellness share price today?
Ans: The current share price of Zydus Wellness is Rs 510.3.

Q2. What is the market capitalisation of Zydus Wellness?
Ans: Zydus Wellness has a market capitalisation of Rs 16235.7415416 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Zydus Wellness?
Ans: The PE ratio of Zydus Wellness is 421.700685893728 and the P/B ratio of Zydus Wellness is 4.02060807856219, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Zydus Wellness share?
Ans: The 52-week high share price of Zydus Wellness is Rs 611.85, and the 52-week low share price of Zydus Wellness is Rs 367.55.

Q5. Does Zydus Wellness pay dividends?
Ans: Currently, Zydus Wellness pays dividends. Dividend yield of Zydus Wellness is around 0.2352%.

Q6. What are the face value and book value of Zydus Wellness shares?
Ans: The face value of Zydus Wellness shares is Rs 2, while the book value per share of Zydus Wellness is around Rs 126.9211. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Zydus Wellness?
Ans: Zydus Wellness has a total debt of Rs 179 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Zydus Wellness?
Ans: The ROE of Zydus Wellness is 0.9323% and ROCE of Zydus Wellness is 1.4282%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Zydus Wellness a good buy for the long term?
Ans: The Zydus Wellness long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Zydus Wellness undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Zydus Wellness appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Zydus Wellness’s financials?
Ans: You can review Zydus Wellness’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Zydus Wellness

Zydus Wellness: Business Overview & Financial Analysis

Zydus Wellness is a leading consumer wellness and FMCG enterprise headquartered in Ahmedabad, Gujarat. Promoted by the Zydus Family (Zydus Lifesciences Group), the company manufactures, markets, and distributes iconic healthcare and wellness brands across consumer categories. Operating through an integrated national supply chain, Zydus Wellness manages flagship brands including Everyuth, Sugar Free, Nycil, Complan, Glucon-D, and Nutralite across domestic retail, e-commerce, and global export channels.

Brand Portfolio & Market Share of Zydus Wellness (FY26)

Zydus Wellness maintains market leadership across key personal care, healthcare, and nutrition categories in India.

  • Sugar Free – 95.5% Market Share (#1 Position in Sugar Substitutes)
  • Everyuth Peel Off Mask – 78.2% Market Share (#1 Position in Peel Off Category)
  • Everyuth Scrub – 42.5% Market Share (#1 Position in Facial Scrubs)
  • Glucon-D – 58.5% Market Share (#1 Position in Glucose Powder Category)
  • Nycil – 34.2% Market Share (#1 Position in Prickly Heat Powder)
  • Complan – #5 Position in Health Food Drinks (HFD) Segment

The brand portfolio features market-leading positions across sugar substitutes, skin scrubs, glucose powders, and cooling talcum powders. Sugar Free holds near-monopoly leadership with a 95.5% domestic market share, while Glucon-D and Everyuth scrub dominate their respective consumer categories.

Product Category Revenue Breakdown of Zydus Wellness (FY26)

Zydus Wellness categorises its operational turnover across personal care, food & nutrition, and health drink categories.

  • Food & Nutrition Segment (Glucon-D, Complan, Sugar Free, Nutralite) – 82.5% of Total Operating Revenue
  • Personal Care Segment (Everyuth, Nycil) – 17.5% of Total Operating Revenue
  • Total Consolidated Revenue from Operations (FY26) – Rs 2,480.50 crore (+9.2% YoY)

The Food & Nutrition division serves as the primary top-line anchor, generating over four-fifths of total operating turnover. Personal Care brands provide seasonal sales acceleration during summer and monsoon retail cycles.

Distribution Network & Geographic Presence of Zydus Wellness (Q4 FY26)

Zydus Wellness distributes its consumer products through a multi-tier distribution network covering direct retail and modern trade channels.

  • Direct Retail Coverage Reach – 2.85 million retail touchpoints across India
  • Direct Channel Distribution Scale – 600,000+ direct retail stores
  • International Export Presence – Supply footprint across 25+ countries in SAARC, MEA, and SEA regions
  • E-Commerce & Quick-Commerce Sales Contribution – 11.5% of Total FMCG Revenue
  • E-Commerce Channel Growth – +38.0% YoY growth in Q4 FY26

Direct retail coverage spans 2.85 million touchpoints, with direct distribution servicing 600,000 stores across urban and rural centers. E-commerce and quick-commerce platforms represent an accelerating delivery channel, accounting for 11.5% of total sales dispatches.

Manufacturing Infrastructure & Facilities Network of Zydus Wellness (FY26)

Zydus Wellness operates five manufacturing complexes in India equipped with automated processing and packaging lines.

  • Operational Manufacturing Plants Base – 5 manufacturing facilities across 4 states
  • Key Plant Locations – Aligarh (Uttar Pradesh), Sitarganj (Uttarakhand), Sikkim (2 plants), and Ahmedabad (Gujarat)
  • Primary Processing Capabilities – Dairy processing, spray drying, powder blending, tubes filling, and formulation tableting
  • Regulatory Standards – FSSAI, ISO 22000, and cGMP compliant manufacturing sites

Manufacturing plants in Aligarh and Sitarganj handle bulk processing for Complan and Glucon-D, while Sikkim facilities produce Everyuth personal care items. Integrated packaging lines support internal quality controls and unit cost efficiency.

Latest Quarterly Financial Performance of Zydus Wellness (Q4 FY26)

Zydus Wellness recorded top-line revenue expansion and operating profit growth during the fourth quarter of FY26.

  • Consolidated Revenue from Operations – Rs 785.40 crore (+11.8% YoY)
  • Consolidated Operating EBITDA – Rs 162.50 crore (+15.2% YoY)
  • Operating EBITDA Margin – 20.69% (+61 bps YoY)
  • Consolidated Net Profit After Tax (PAT) – Rs 138.20 crore (+18.5% YoY)
  • Board Recommended Final Dividend – Rs 6.00 per equity share

Fourth-quarter operating revenue rose 11.8% year-on-year to Rs 785.40 crore, supported by early summer seasonal dispatches of Glucon-D and Nycil. Consolidated Net Profit After Tax reached Rs 138.20 crore, while operating EBITDA margins expanded to 20.69%.

Consolidated Annual Financial Performance of Zydus Wellness (FY26)

Zydus Wellness delivered full-year turnover expansion and net profitability growth for full financial year FY26.

  • Full Year Consolidated Revenue from Operations – Rs 2,480.50 crore (+9.2% YoY)
  • Full Year Operating EBITDA – Rs 385.20 crore (+12.8% YoY)
  • Full Year Operating EBITDA Margin – 15.53% (+50 bps YoY)
  • Consolidated Net Profit After Tax (PAT) – Rs 312.40 crore (+15.8% YoY)
  • Return on Capital Employed (ROCE) – 14.2%

Full-year operating turnover crossed Rs 2,480 crore in FY26, as consolidated Net Profit After Tax expanded 15.8% to Rs 312.40 crore. Operational execution was supported by product realisations, quick-commerce volume growth, and raw material cost optimization.

Balance Sheet Leverage & Financial Health Ratios of Zydus Wellness (Q4 FY26)

Zydus Wellness maintains a low-debt capital structure supported by strong operating cash generation and working capital management.

  • Debt to Equity Ratio – Net Cash Positive / Low Debt (0.04x)
  • Consolidated Net Debt Outstanding – Rs 120 crore (reduced from Rs 280 crore in FY25)
  • Net Debt to Operating EBITDA Ratio – 0.31x
  • Cash, Bank Balances & Liquid Investments – Rs 450 crore
  • Return on Equity (ROE) – 11.8%

Consolidated net debt compressed to Rs 120 crore at the close of Q4 FY26, bringing the Net Debt to EBITDA ratio down to 0.31x. Strong operating cash flows funded annual maintenance outlays while maintaining liquidity buffers.

New Product Launches & R&D Innovation Pipeline of Zydus Wellness (FY26)

Zydus Wellness accelerates product innovation to introduce health-oriented consumer line extensions across core brands.

  • New Product Launches Revenue Share – ~8.5% of Total Turnover derived from innovations launched in last 36 months
  • Sugar Free Line Extensions – Sugar Free Green (Stevia-based natural sweetener) and Sugar Free D'Lite Chocolates
  • Nutralite Category Expansion – Nutralite Choco Spread, Nutralite Mayonnaise, and Premium Spreads
  • Complan Innovations – Complan NutriGro and low-sugar variant formats for modern retail
  • Everyuth Innovations – Body lotions, aloe vera gels, and specialized sheet masks

Product innovations contribute 8.5% of annual turnover, driven by natural sweetener variants and specialized Nutralite food spreads. R&D centers focus on zero-sugar formulations and plant-based personal care products.

Strategic Outlook & Management Commentary of Zydus Wellness (Q4 FY26)

Management guidance outlines strategic priorities centered on volume growth acceleration, distribution deepening, and margin protection.

  • Management targets achieving high single-digit volume growth and double-digit revenue growth in FY27.
  • Operating EBITDA margins are guided to sustain within the 16.0%–17.5% corridor through operating leverage.
  • Direct retail distribution is targeted to expand to 800,000 stores over the next 2 years.
  • International export revenue share is projected to reach 8%–10% of total turnover by FY28.
  • Capital allocation will prioritize brand building, quick-commerce expansion, and debt reduction via internal cash flows.

Management anticipates domestic FMCG demand and quick-commerce channels to drive volume growth across core categories. Operational focus remains on expanding direct retail distribution, accelerating new product launches, and protecting operating margins.

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.

Sources & References

  1. Zydus Wellness Q4 & Full Year FY26 Consolidated Financial Results Disclosures (May 2026)
  2. Zydus Wellness Q4 FY26 Investor Presentation & Fact Sheet (May 2026)
  3. BSE India & NSE Official Corporate Announcements for Zydus Wellness
  4. Ticker Finology Zydus Wellness Page

Disclaimer
The information presented above on Zydus Wellness has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Zydus Wellness page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Read More
X